

# Michael J Econs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7631431/publications.pdf>

Version: 2024-02-01

67  
papers

8,545  
citations

126907

33  
h-index

114465

63  
g-index

70  
all docs

70  
docs citations

70  
times ranked

8213  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel PHEX gene locus-specific database: Comprehensive characterization of vast number of variants associated with X-linked hypophosphatemia (XLH). <i>Human Mutation</i> , 2022, 43, 143-157.	2.5	18
2	Unusual Cortical Phenotype After Hematopoietic Stem Cell Transplantation in a Patient With Osteopetrosis. <i>JBMR Plus</i> , 2022, 6, .	2.7	1
3	Case 18-2022: A 29-Year-Old Woman with Recurrent Fractures. <i>New England Journal of Medicine</i> , 2022, 386, 2316-2326.	27.0	2
4	Radiographic imaging, densitometry and disease severity in Autosomal dominant osteopetrosis type 2. <i>Skeletal Radiology</i> , 2021, 50, 903-913.	2.0	6
5	Chloroquine increases osteoclast activity in vitro but does not improve the osteopetrotic bone phenotype of ADO2 mice. <i>Bone</i> , 2021, 153, 116160.	2.9	1
6	Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Iron-Deficient Patients With Autosomal Dominant Hypophosphatemic Rickets. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 231-238.	2.8	32
7	Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 432.	7.4	162
8	Disentangling the genetics of lean mass. <i>American Journal of Clinical Nutrition</i> , 2019, 109, 276-287.	4.7	38
9	Meta-Analysis of Genomewide Association Studies Reveals Genetic Variants for Hip Bone Geometry. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1284-1296.	2.8	27
10	Interferon Gamma-1b Does Not Increase Markers of Bone Resorption in Autosomal Dominant Osteopetrosis. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1436-1445.	2.8	16
11	OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	2
12	Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels. <i>Nature Communications</i> , 2018, 9, 260.	12.8	295
13	Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-222851.	0.5	36
14	Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies. <i>Journal of Clinical Investigation</i> , 2018, 128, 5368-5373.	8.2	27
15	A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice. <i>Endocrinology</i> , 2017, 158, 470-476.	2.8	21
16	Bone Mass and Strength are Significantly Improved in Mice Overexpressing Human WNT16 in Osteocytes. <i>Calcified Tissue International</i> , 2017, 100, 361-373.	3.1	16
17	Osteopetroses, emphasizing potential approaches to treatment. <i>Bone</i> , 2017, 102, 50-59.	2.9	53
18	Large meta-analysis of genome-wide association studies identifies five loci for lean body mass. <i>Nature Communications</i> , 2017, 8, 80.	12.8	147

#	ARTICLE	IF	CITATIONS
19	Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3111-3123.	3.6	170
20	Phenotypic severity of autosomal dominant osteopetrosis type II (ADO2) mice on different genetic backgrounds recapitulates the features of human disease. <i>Bone</i> , 2017, 94, 34-41.	2.9	11
21	Genetic diseases resulting from disordered FGF23/klotho biology. <i>Bone</i> , 2017, 100, 56-61.	2.9	10
22	Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1845-1854.	2.8	67
23	Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women. <i>Bone</i> , 2016, 86, 98-105.	2.9	36
24	Genome-wide association study of serum iron phenotypes in premenopausal women of European descent. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 57, 50-53.	1.4	3
25	Osteoblast-Specific Overexpression of Human WNT16 Increases Both Cortical and Trabecular Bone Mass and Structure in Mice. <i>Endocrinology</i> , 2016, 157, 722-736.	2.8	43
26	Interferon Gamma, but not Calcitriol Improves the Osteopetrotic Phenotypes in ADO2 Mice. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 2005-2013.	2.8	24
27	Conventional Therapy in Adults With XLH Improves Dental Manifestations, But Not Enthesopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3622-3624.	3.6	16
28	The Case   Ectopic calcifications in a child. <i>Kidney International</i> , 2015, 87, 1079-1081.	5.2	2
29	Fine mapping of bone structure and strength QTLs in heterogeneous stock rat. <i>Bone</i> , 2015, 81, 417-426.	2.9	11
30	Phenotypic Dissection of Bone Mineral Density Reveals Skeletal Site Specificity and Facilitates the Identification of Novel Loci in the Genetic Regulation of Bone Mass Attainment. <i>PLoS Genetics</i> , 2014, 10, e1004423.	3.5	134
31	Intronic deletions in the SLC34A3 gene: A cautionary tale for mutation analysis of hereditary hypophosphatemic rickets with hypercalciuria. <i>Bone</i> , 2014, 59, 53-56.	2.9	13
32	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. <i>Nature</i> , 2014, 514, 92-97.	27.8	548
33	SIBLING family genes and bone mineral density: Association and allele-specific expression in humans. <i>Bone</i> , 2014, 64, 166-172.	2.9	10
34	Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models. <i>Bone</i> , 2014, 59, 66-75.	2.9	36
35	Iron and fibroblast growth factor 23 in X-linked hypophosphatemia. <i>Bone</i> , 2014, 60, 87-92.	2.9	29
36	Dosage Effect of a PheX Mutation in a Murine Model of X-Linked Hypophosphatemia. <i>Calcified Tissue International</i> , 2013, 93, 155-162.	3.1	17

#	ARTICLE	IF	CITATIONS
37	A <i>Phex</i> mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 453-460.	2.8	34
38	Iron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3541-3549.	3.6	250
39	Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1846-1850.	3.6	138
40	Ablation of the Galnt3 Gene Leads to Low-Circulating Intact Fibroblast Growth Factor 23 (Fgf23) Concentrations and Hyperphosphatemia Despite Increased Fgf23 Expression. <i>Endocrinology</i> , 2009, 150, 2543-2550.	2.8	135
41	CLCN7 polymorphisms and bone mineral density in healthy premenopausal white women and in white men. <i>Bone</i> , 2008, 43, 995-998.	2.9	5
42	Meta-Analysis of Genome-Wide Scans Provides Evidence for Sex- and Site-Specific Regulation of Bone Mass. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 173-183.	2.8	144
43	Autosomal Dominant Osteopetrosis: Clinical Severity and Natural History of 94 Subjects with a Chloride Channel 7 Gene Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 771-778.	3.6	129
44	Novel GALNT3 Mutations Causing Hyperostosis-Hyperphosphatemia Syndrome Result in Low Intact Fibroblast Growth Factor 23 Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1943-1947.	3.6	76
45	FGF23 Concentrations Vary With Disease Status in Autosomal Dominant Hypophosphatemic Rickets. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 520-526.	2.8	149
46	A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. <i>Journal of Clinical Investigation</i> , 2007, 117, 2684-2691.	8.2	390
47	Polymorphisms in the bone morphogenetic protein 2 (BMP2) gene do not affect bone mineral density in white men or women. <i>Osteoporosis International</i> , 2006, 17, 587-592.	3.1	13
48	Confirmation of Linkage to Chromosome 1q for Peak Vertebral Bone Mineral Density in Premenopausal White Women. <i>American Journal of Human Genetics</i> , 2004, 74, 223-228.	6.2	46
49	Most Osteomalacia-associated Mesenchymal Tumors Are a Single Histopathologic Entity. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1-30.	3.7	587
50	Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia. <i>New England Journal of Medicine</i> , 2003, 348, 1656-1663.	27.0	853
51	FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. <i>Journal of Clinical Investigation</i> , 2003, 112, 683-692.	8.2	567
52	Genetics of Osteoporosis. , 2002, 23, 303-326.		115
53	Sibling Pair Linkage and Association Studies between Peak Bone Mineral Density and the Gene Locus for the Osteoclast-Specific Subunit (OC116) of the Vacuolar Proton Pump on Chromosome 11p12-13. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3819-3824.	3.6	10
54	Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. <i>Kidney International</i> , 2001, 60, 2079-2086.	5.2	443

#	ARTICLE	IF	CITATIONS
55	Genome Screen for Quantitative Trait Loci Underlying Normal Variation in Femoral Structure. Journal of Bone and Mineral Research, 2001, 16, 985-991.	2.8	106
56	Hypophosphatemic rickets. , 2001, 2, 165-173.		17
57	The Autosomal Dominant Hypophosphatemic Rickets (ADHR) Gene Is a Secreted Polypeptide Overexpressed by Tumors that Cause Phosphate Wasting. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 497-500.	3.6	292
58	The Autosomal Dominant Hypophosphatemic Rickets (ADHR) Gene Is a Secreted Polypeptide Overexpressed by Tumors that Cause Phosphate Wasting. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 497-500.	3.6	111
59	Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nature Genetics, 2000, 26, 345-348.	21.4	1,411
60	Sibling Pair Linkage and Association Studies between Bone Mineral Density and the Insulin-Like Growth Factor I Gene Locus1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4467-4471.	3.6	52
61	Non-random distribution of mutations in the PHEX gene, and under-detected missense mutations at non-conserved residues. European Journal of Human Genetics, 1999, 7, 615-619.	2.8	60
62	Osteopathia Striata with Cranial Sclerosis. Journal of Bone and Mineral Research, 1999, 14, 152-153.	2.8	14
63	Bone mineral density and laboratory evaluation of a type II autosomal dominant osteopetrosis carrier. , 1999, 85, 9-12.		7
64	Chromosomal localization of two human genes involved in phosphate homeostasis: the type IIb sodium-phosphate cotransporter and stanniocalcin-2. Somatic Cell and Molecular Genetics, 1998, 24, 357-362.	0.7	25
65	Localization of PiUS, a stimulator of cellular phosphate uptake to human chromosome 3p21.3. Somatic Cell and Molecular Genetics, 1998, 24, 71-74.	0.7	3
66	Autosomal Dominant Hypophosphatemic Rickets/Osteomalacia: Clinical Characterization of a Novel Renal Phosphate-Wasting Disorder. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 674-681.	3.6	267
67	Chapter 23. Fibroblast Growth Factor-23. , 0, , 112-116.		6